

Antonio Chistolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637355/publications.pdf>

Version: 2024-02-01

40
papers

451
citations

759055

12
h-index

752573

20
g-index

41
all docs

41
docs citations

41
times ranked

761
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. <i>Internal and Emergency Medicine</i> , 2022, 17, 1081-1085.	1.0	2
2	Thromboembolic events following mRNA vaccines for COVID 19: a case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 971-973.	1.0	4
3	Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein. <i>Haematologica</i> , 2022, 107, 1687-1692.	1.7	10
4	Immune thrombocytopenia management during COVID-19 pandemic: An Italian monocentric experience. <i>EJHaem</i> , 2022, 3, 453-456.	0.4	5
5	Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. <i>TH Open</i> , 2022, 06, e251-e256.	0.7	2
6	Post-filter thromboembolic prophylaxis in vena cava filter carriers. <i>Phlebology</i> , 2021, 36, 79-80.	0.6	0
7	The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants. <i>Phlebology</i> , 2021, 36, 329-330.	0.6	2
8	Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13356.	1.7	6
9	Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 584-589.	1.0	6
10	Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. <i>Nature Communications</i> , 2021, 12, 4663.	5.8	47
11	Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome. <i>Haemophilia</i> , 2021, 27, e667-e674.	1.0	2
12	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 105-110.	1.0	18
13	Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report. <i>Thrombosis Research</i> , 2021, 208, 14-17.	0.8	4
14	Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. <i>HIV Medicine</i> , 2020, 21, e7.	1.0	2
15	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 4193-4199.	1.0	20
16	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia. <i>Thrombosis Research</i> , 2020, 196, 539-540.	0.8	2
17	Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Clinical Drug Investigation</i> , 2020, 40, 1177-1181.	1.1	2
18	A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with PNH-negative myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2020, 95, E329-E332.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Direct oral anticoagulants for the treatment of Mondorâ€™s disease not responding to low-molecular weight heparin. <i>Phlebology</i> , 2020, 35, 734-735.	0.6	1
20	Effect of low or high doses of lowâ€™molecularâ€™weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVIDâ€™19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	1.2	25
21	Right elbow arthropathy in a patient with severe haemophilia A. <i>British Journal of Haematology</i> , 2020, 190, 484-484.	1.2	0
22	Direct oral anticoagulants in patients with hematologic malignancies. <i>Hematological Oncology</i> , 2020, 38, 589-596.	0.8	8
23	Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 718-723.	1.0	5
24	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 426-430.	1.0	11
25	Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal. <i>Leukemia and Lymphoma</i> , 2020, 61, 2265-2267.	0.6	4
26	Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102903.	0.5	2
27	Role of Factor V R2 Haplotype and Common Thrombophilia Markers as Genetic Risk Factors for Ischemic Stroke. <i>Journal of Stroke Medicine</i> , 2020, 3, 144-150.	0.2	0
28	Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, e503-e504.	0.5	2
29	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e217-e219.	1.2	1
30	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019044.	0.5	16
31	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of <i>MYH9</i> syndrome treated with a TPOâ€™RA. <i>Haemophilia</i> , 2019, 25, e288-e290.	1.0	2
32	Antithrombin concentrate during pregnancy in congenital antithrombin deficiency. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 304-307.	0.5	1
33	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. <i>Blood Transfusion</i> , 2019, 17, 171-180.	0.3	32
34	ABO447â€™...Anti-Phospholipid Positivity in Healthy Subjects: Evaluation of Risk for Thrombotic Event after A 5 Years Follow-Up. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1059.3-1059.	0.5	0
35	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015, 23, 3289-3295.	1.0	39
36	EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014011.	0.5	10

#	ARTICLE	IF	CITATIONS
37	Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1191-1194.	0.7	28
38	Sudden sensorineural hearing loss: A vascular cause? Analysis of prothrombotic risk factors in head and neck. <i>International Journal of Audiology</i> , 2012, 51, 800-805.	0.9	50
39	Role of Genetic and Acquired Prothrombotic Risk Factors in Genesis of Sudden Sensorineural Hearing Loss. <i>Audiology and Neuro-Otology</i> , 2011, 16, 185-190.	0.6	28
40	Endoscopic Evaluation of the Upper Gastrointestinal Tract is Worthwhile in Premenopausal Women with Iron-Deficiency Anaemia Irrespective of Menstrual Flow. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 239-245.	0.6	37